Persistent airway eosinophilia/Th2 inflammation in severe asthma is associated with reduced epithelial SOCS1 expression.
INTRODUCTION
Asthma is one of the most common chronic conditions affecting approximately 300 million people worldwide. [1] Most patients with asthma achieve adequate disease control with bronchodilator and inhaled corticosteroid therapy. [2] However, approximately 10% of patients suffer from severe uncontrolled asthma despite the use of high dose inhaled corticosteroids, and in many cases systemic corticosteroids. This cohort of asthma patients represent a significant unmet clinical need. [3] Asthma is a heterogeneous disorder thus current research is endeavouring to identify and characterise distinct phenotypes, particularly in severe disease. [4, 5] Both clinical and molecular phenotyping have been utilised to describe populations of asthma patients in terms of inflammatory biology. [6] [7] [8] A key feature in many patients with severe asthma is persistent eosinophilic airway inflammation despite high dose corticosteroid treatment. [9, 10] The major group of cytokines implicated in driving this inflammation are the Th2-associated cytokines, namely IL-4, IL-5 and IL-13. IL-13 is a key cytokine contributing to the pathophysiological features of asthma including airway hyper-responsiveness, mucus hypersecretion and airway remodelling and IL-13 overexpression persists in a subgroup of patients with severe asthma despite high dose steroid treatment. [10, 11] Th2 cytokines mediate their actions via the JAK-STAT pathway and cytokine signalling is tightly regulated by several molecules including the suppressors of cytokine signalling (SOCS). SOCS are a family of 8 proteins, comprising SOCS1-7 and CIS, which inhibit cytokine signalling through inhibition of the JAK-STAT pathway in a negative feedback manner. [12] SOCS1 was the first of the SOCS family to be discovered. [13] In vitro cell cultures and in vivo animal models have demonstrated that SOCS1 is a negative regulator of Th2-dependent pathways, achieved by inhibition of the phosphorylation of STAT6. [14, 15] SOCS2 inhibits growth hormone and insulin-like growth factor [16] and has been shown to regulate the expression of other SOCS molecules. [17] Recently, we have shown that SOCS2 knockout mice have an increased susceptibility to Th2 mediated airway inflammation compared to wild type mice, due to elevated SOCS3 levels. [18] SOCS3 mRNA expression is reported to be increased in the peripheral T cells of asthma patients [19, 20] and constitutive SOCS3 expression in the T cells of mice resulted in exaggerated lung inflammation in a mouse model of asthma. [20] The principal aim of this study was to examine SOCS1, SOCS2 and SOCS3 expression in the airways of healthy controls, mild/moderate asthmatics and severe asthmatics and to explore the relationship between SOCS expression and persistent eosinophilic inflammation within the airway.
METHODS

Patient cohort
Data from this well characterised cohort of subjects has been published previously. [10, 21, 22] Healthy controls (n=17), mild/moderate asthmatics (n=29) and severe asthmatics (n=18) were recruited from two UK specialist asthma centres, Belfast City Hospital and Glenfield Hospital, Leicester (demographic characteristics shown in Table 1 ).
Clinical assessment protocols ensured patients had severe asthma as defined by current ERS/ATS guidelines. [23] Further details of asthma patients in the study, including asthma treatment, can be found in the online supplementary file (Table E1 ). This study was approved by Research Ethics Committees of both institutions and written informed consent obtained from all subjects (see online supplementary file). 
Bronchoscopy
Each participant underwent bronchoscopy and biopsy specimens were taken from the right middle lobe and lower lobe carinae. Biopsies were immediately placed in RNA preservative (Ambion, USA) or fixed overnight before embedding in glycol methacrylate (GMA) as described previously. [24] 
Gene expression analyses
Bronchial biopsies were homogenised, RNA extracted and amplified for Agilent two colour Whole Human Genome 4x44k gene expression microarray analysis as previously described. [25] Th2 score was calculated as described previously and details can be found in the online supplementary file. [8, 10, 25] TaqMan® Gene Expression Assays (Applied Biosystems, USA) were used as per manufacturer's instructions. GAPDH was utilised as the house keeping gene. qPCR values were calculated using the ΔΔCt method with relative gene expression calculated as -ΔΔCt. [26] Further details are available in the online supplementary file.
Immunohistochemistry (IHC)
Sections of bronchial biopsies were cut at 2µm, immunostained as described previously [24] and counterstained with Mayer's haematoxylin. Negative controls, using an isotype and/or omitting primary antibody, were employed. The lamina propria was measured in biopsy sections using a computer analysis system (LAS V3.7 software, Leica, Germany). For enumerating cellular inflammatory infiltrate, individual positively stained nucleated cells were counted and expressed per mm 2 of tissue. Figure E1 in the online supplementary file shows exemplar micrographs of inflammatory cell staining. IHC was additionally employed to determine localisation of SOCS proteins in patient biopsies. Full details of antibodies are available in the online supplementary file.
Bronchial epithelial cell cultures
The BEAS-2B cell line (ATCC, USA) was cultured in Dulbecco's Modified Eagle Medium supplemented with 5% foetal calf serum and 1% Penicillin/Streptomycin. Primary bronchial epithelial cells (PBECs) were obtained from healthy volunteers. This work was approved by
Research Ethics Committee as detailed in the online supplementary file and written informed consent was gained from all subjects. [22] PBECs were cultured in airway epithelial cell basal medium containing a supplement pack (Promocell, Germany). Human recombinant IL-13
(R&D Systems, USA) was used at 50 ng/ml. In vitro experiments were carried out a minimum of 3 times.
Transfections
Myc-tagged full-length SOCS1 in a pcDNA3 plasmid, along with the empty vector, were a generous gift from Prof. A. Yoshimura (Keio University School of Medicine, Japan). BEAS-2B cells were plated in antibiotic-free media and transfected using Lipofectamine 2000 (Invitrogen, UK). PBECs were transfected by electroporation using the NEON transfection system (Life Technologies, UK). Media was changed 6 hours post-transfection and cell stimulations were carried out 24 hours post-transfection.
Western blotting
Cells were lysed and 30 µg of protein was immunoblotted with antibodies against SOCS1, SOCS2, SOCS3, c-Myc and γ-tubulin as described in the online supplementary file.
Statistical analyses
GraphPad, 
RESULTS
Increased Th2 inflammatory measures in study participants with asthma.
Peripheral blood eosinophil numbers and blood IgE levels were significantly elevated in mild/moderate asthmatics and severe asthmatics as compared to healthy controls ( Figure 1A and 1B respectively). Quantification of eosinophils using IHC showed a trend of increasing numbers of eosinophils in the lamina propria of bronchial biopsies with increasing asthma severity (healthy control, mild/moderate asthma and severe asthma group median values were 4.59, 9.70 and 12.93 respectively, p=0.07) ( Figure 1C ). There were no significant differences noted in the number of neutrophils or mast cells between the study groups ( Table E2 in the online supplementary file). The previously generated gene expression microarray Th2 signature from asthma patients is a composite measure of IL-13 induced epithelial genes. [8, 10, 25] There was also a trend for increasing Th2 biopsy signature values with increasing asthma severity (p=0.057). There was a significant positive correlation between the intensity of the Th2 biopsy signature and the number of eosinophils/mm 2 of lamina propria of the asthma patients ( Figure 1E ). No correlation was observed between neutrophils or mast cells and the Th2 signature ( Figure E2 in the online supplementary file).
Decreased SOCS1 mRNA expression in bronchial biopsies from severe asthmatics compared to mild/moderate asthmatics.
Gene expression of SOCS1, SOCS2 and SOCS3 mRNA in bronchial biopsies of healthy controls, mild/moderate asthmatics and severe asthmatics was assessed using qPCR. SOCS1
expression was significantly decreased in the bronchial biopsies of severe asthmatics compared to mild/moderate asthmatics ( Figure 2A ). However, there were no differences observed in SOCS2 and SOCS3 gene expression levels between groups ( Figure 2B and 2C respectively). Of note SOCS1 mRNA was decreased in the airways of asthma patients receiving high dose inhaled corticosteroids compared those receiving low dose inhaled corticosteroids but there was no difference in SOCS2 or SOCS3 expression ( Figure E3 ).
SOCS1 gene expression is decreased in patients with persistent Th2 inflammation and eosinophilia in the airways.
Significant negative correlations were observed between SOCS1 gene expression and both the Th2 biopsy signature and eosinophil numbers in the lamina propria of bronchial tissue in asthma patients ( Figure 3A and 3B respectively). There were no significant correlations identified between SOCS2 or SOCS3 and Th2 biopsy signature or eosinophil numbers in bronchial biopsies ( Figure E4 in the online supplementary file). To further examine the relationship between SOCS1 expression and tissue eosinophilia, subjects were dichotomised by the number of eosinophils in the lamina propria of their bronchial biopsies (eosinophil counts were dichotomised around the median value for eosinophils/mm 2 within the lamina propria). Participants with high eosinophils (≥9.2 eosinophils/mm 2 within the lamina propria)
were found to have significantly decreased levels of SOCS1 when compared to those presenting with low eosinophils (<9.2 eosinophils/mm 2 within the lamina propria) ( Figure   3C ). Subjects dichotomised into eosinophil high and eosinophil low subsets again showed no difference in SOCS2 or SOCS3 expression between the two groups ( Figure E5 in the online supplementary file). As CCL26 is highly induced in response to type 2 inflammation the relationship between this chemokine and SOCS1 was explored. As anticipated a negative correlation was observed indicating patients with low SOCS1 expression fail to inhibit the Th2 induced CCL26 ( Figure 3D ).
Localisation of SOCS proteins in bronchial biopsies.
To examine the cellular localisation of SOCS protein expression, IHC was employed to stain for SOCS1, SOCS2 and SOCS3 in the bronchial biopsies. SOCS1 was localised predominantly to the bronchial epithelium and observed in the differentiated pseudocolumnar cells rather than the basal cells ( Figure 4 shows representative images of A, negative control staining, and SOCS1 staining of B, healthy controls, C, mild/moderate asthmatics and D, severe asthmatics). There was minimal SOCS2 staining evident throughout the bronchial biopsies with only a small number of infiltrating inflammatory cells in the lamina propria staining positive for SOCS2 ( Figure E6 in the online supplementary file).
SOCS3 was found to be present both in the epithelium and in large, mononuclear/macrophage like cells in the lamina propria ( Figure E6 in the online supplementary file).
Inhibition of IL-13 induced CCL26 mRNA in bronchial epithelial cell SOCS1 overexpression models.
Due to the localisation of SOCS1 to the bronchial epithelium and its potential role in inhibiting Th2 inflammation within the severe asthmatic airway, the BEAS-2B cell line was initially used to further characterise the role of SOCS1 in IL-13 signalling in the bronchial epithelium. We examined induction of SOCS1 mRNA in BEAS-2B cells after IL-13
(50 ng/ml) exposure and found it was rapidly up-regulated within 2 hours of stimulation and remained elevated over the 24 hour time course. SOCS2 and SOCS3 mRNA were not induced in response to IL-13 treatment ( Figure 5A ). We then investigated the expression of SOCS1, SOCS2 and SOCS3 protein in response to IL-13 stimulation observing SOCS1 but not SOCS2 or SOCS3 induction ( Figure 5B ). CCL26 (eotaxin-3) mRNA is upregulated in vitro by IL-13 stimulation and in bronchial biopsies of asthma patients with high levels of
Th2 inflammation in their airways. [25] CCL26 mRNA upregulation was confirmed in BEAS2-B cultures stimulated with IL-13 ( Figure 5C ). To investigate the role of SOCS1 in the regulation of IL-13 induced CCL26, SOCS1 was overexpressed in BEAS-2B cells using a Myc-tagged SOCS1 plasmid. Transfection with the SOCS1 plasmid lead to overexpression of SOCS1 in the cells compared to the empty vector control ( Figure 5D ). Next, cells were transfected with either the empty vector or the Myc-tagged SOCS1 plasmid for 24 hours, then stimulated with IL-13 for a further 24 hours. A significant decrease in CCL26 mRNA was observed in the SOCS1 overexpressing cells ( Figure 5D ).
We then wished to confirm these observations in primary bronchial epithelial cells (PBECs).
PBECs were stimulated with IL-13 (50 ng/ml) over a 24 hour time course. SOCS1 mRNA was again rapidly up-regulated 2 hours after stimulation and remained elevated over the 24
hour time course and SOCS2 and SOCS3 mRNA were not induced ( Figure 6A ). As anticipated, CCL26 mRNA was also induced in IL-13-stimulated cells ( Figure 6B ). PBECs were transfected using electroporation (transfection efficiencies were routinely greater than 55% as shown in Figure E7 ) and again, overexpression of SOCS1 reduced IL-13 induction of CCL26 mRNA compared to empty vector control ( Figure 6C ).
DISCUSSION
Severe asthma affects up to 10% of all asthma patients, but the underlying mechanisms causing persistent eosinophilic inflammation, despite high dose inhaled corticosteroid treatment, are yet to be fully elucidated. [10, 27] SOCS molecules have been shown to regulate Th2 cytokine signalling both in vitro and in in vivo mouse models of allergic airway inflammation, however, it is unclear if similar regulatory mechanisms exist in human asthma.
In this study we investigated, for the first time, the expression of SOCS1, SOCS2 and SOCS3
in the airways of healthy controls, mild/moderate asthmatics and severe asthmatics. We show that patients with severe asthma and persistent eosinophilic airway inflammation have decreased epithelial SOCS1 expression compared to patients with milder more stable asthma.
This reduced SOCS1 was inversely associated with an IL-13-dependent Th2 gene signature and tissue eosinophilia, which appears paradoxical, as one would anticipate IL-13 signalling to be associated with increased SOCS1 expression in an attempt to 'switch off' IL-13 driven responses. It is worth commenting that baseline SOCS1 expression in healthy subjects is low (and not different from severe asthmatics), presumably reflecting the absence of proinflammatory cytokine stimuli and thus no requirement for the negative feedback regulator.
The key difference is that in the severe asthma population with persistent Th2 signalling and eosinophilia, the failure of SOCS1 up-regulation is inappropriate.
This effect appears specific for SOCS1, as we identified no differences in SOCS2 or SOCS3 expression in relation to disease severity, Th2 signature, or eosinophilic inflammatory infiltrate. SOCS2 and SOCS3 have been implicated in animal models of asthma and SOCS molecules can interact with each other. For example, SOCS2 has been shown to regulate the expression of SOCS1 and SOCS3 via direct interactions [17] and SOCS2 knockout mice were shown to have elevated levels of SOCS1 and SOCS3 in T cells. [18] However, our data examining the expression of SOCS molecules in human asthma suggests a specific dysregulation of SOCS1 in severe asthma with persistent Th2 inflammation despite high dose inhaled corticosteroids. One limiting factor of our study is the cross sectional design, therefore we cannot comment on the dynamic changes in SOCS expression. However, the pattern of specific SOCS1 down-regulation was consistent across severe asthma patients with persistent eosinophilia thus suggesting that it is unlikely to be a transient feature.
We utilised immunohistochemistry to examine localisation of SOCS proteins and better inform our subsequent in vitro mechanistic analysis. SOCS1 was found to be localised predominantly to the bronchial epithelium of the airway tissue. This is consistent with previous data, whereby mice challenged intra-tracheally with IL-13 displayed SOCS1
induction localised to the airway epithelium. [15] In vitro studies and in vivo animal models have shown SOCS1 attenuates Th2 inflammation.
Local airway induction of SOCS1 in response to IL-13 administration in an in vivo mouse model was associated with suppression of eotaxin levels. [15] In another study, an OVAinduced airway inflammation model was utilised and SOCS1 -/ -IFN-γ -/mice had increased eosinophilic infiltration in the lungs and elevated Th2 cytokines compared to IFN-γ -/control mice. [14] These animal studies support our data in human asthma whereby reduced SOCS1 expression in severe asthma is also associated with airway eosinophilia and an IL-13dependent Th2 gene signature, suggesting epithelial SOCS1 has a central role in regulating IL-13 signalling in the airway and airway eosinophilia. Indeed high SOCS1 expression in airway eosinophils has been reported to inhibit their response to the IL-5 family cytokines. [28] Therefore SOCS1 deficiency in eosinophils in the airway of severe asthma patients may cause increased sensitivity to IL-5 cytokine signaling leading to enhanced eosinophil survival and pathologies in the airway.
IL-13 is a Th2 cytokine that has been implicated in human asthma and is elevated in severe asthma subjects with persistent eosinophilia. [10, 29] IL-13 signals via the STAT6 pathway and the absolute requirement of SOCS1 in attenuating Th2 inflammation via inhibition of STAT6 phosphorylation has been observed in SOCS1 deficient mouse embryonic fibroblasts. [15, 30] As SOCS1 was localised to the bronchial epithelium of bronchial biopsies, we wished to examine the role of SOCS1 in regulating IL-13 epithelial signalling in vitro using the bronchial epithelial BEAS-2B cell line and primary bronchial epithelial cells (PBECs A study assessing functional variants of SOCS1 within a population of adult Japanese asthma patients found a significant association between the SOCS1 promoter polymorphism, -1478CA< del, and adult asthma. It is suggested this promoter polymorphism leads to increased SOCS1 and inhibition of interferons (IFNs) leading to higher susceptibility to virus-induced asthma exacerbations. [35] Another study has recently shown that increased nuclear SOCS1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate IFNs. [36] However, our data in severe asthmatics would suggest that reduced SOCS1 in the epithelium is associated with persistent eosinophilia, which is a major risk factor for exacerbations in this population. [37] In summary, we have investigated the expression of SOCS1, SOCS2 and SOCS3 within the airways of healthy controls, mild/moderate asthmatics, and severe asthmatics. We found that SOCS1 was significantly decreased in the airways of severe asthma patients when compared to mild/moderate asthma patients. Subjects with persistent eosinophilia and increased Th2 inflammation within the airway have decreased epithelial SOCS1 expression. In vitro investigation of BEAS-2B and primary bronchial epithelial cell cultures showed that SOCS1 was induced in response to IL-13 stimulation and SOCS1 overexpression led to reduced CCL26 mRNA induction in response to IL-13 stimulation. Further work will focus on why there is an inappropriate failure to upregulate SOCS1 in the epithelium of patients with severe asthma despite persistent Th2 signalling in the airway. Cells were then treated with an empty vector or SOCS1 overexpression plasmid for 24 hours, stimulated with IL-13 for a further 24 hours then CCL26 mRNA was measured using qPCR.
Figure legends
Graphs show median and IQR. Mann-Whitney U test employed for statistical analysis (n=4).
*P<0.05. 
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